First Trust Advisors LP trimmed its holdings in NxStage Medical, Inc. (NASDAQ:NXTM) by 17.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 35,611 shares of the medical device company’s stock after selling 7,508 shares during the period. First Trust Advisors LP owned about 0.05% of NxStage Medical worth $893,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of the business. New Jersey Better Educational Savings Trust acquired a new position in shares of NxStage Medical during the second quarter worth about $451,000. Schwab Charles Investment Management Inc. boosted its position in shares of NxStage Medical by 0.8% during the second quarter. Schwab Charles Investment Management Inc. now owns 280,092 shares of the medical device company’s stock worth $7,022,000 after buying an additional 2,193 shares during the period. Trexquant Investment LP boosted its position in shares of NxStage Medical by 105.5% during the second quarter. Trexquant Investment LP now owns 17,387 shares of the medical device company’s stock worth $436,000 after buying an additional 8,926 shares during the period. Parkwood LLC acquired a new position in shares of NxStage Medical during the second quarter worth about $555,000. Finally, Quantitative Systematic Strategies LLC acquired a new position in shares of NxStage Medical during the second quarter worth about $203,000. 92.75% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “NxStage Medical, Inc. (NXTM) Shares Sold by First Trust Advisors LP” was published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/09/22/nxstage-medical-inc-nxtm-shares-sold-by-first-trust-advisors-lp.html.

In other news, SVP Matthew W. Towse sold 4,300 shares of the firm’s stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $24.16, for a total value of $103,888.00. Following the completion of the sale, the senior vice president now directly owns 28,721 shares in the company, valued at approximately $693,899.36. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, President Joseph E. Turk, Jr. sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, July 5th. The shares were sold at an average price of $25.19, for a total value of $25,190.00. Following the completion of the sale, the president now owns 75,903 shares of the company’s stock, valued at $1,911,996.57. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 50,400 shares of company stock valued at $1,403,650. 4.70% of the stock is currently owned by company insiders.

Several research analysts have recently weighed in on NXTM shares. Craig Hallum started coverage on NxStage Medical in a research report on Tuesday, June 27th. They set a “buy” rating and a $32.00 price objective for the company. BidaskClub raised NxStage Medical from a “hold” rating to a “buy” rating in a research report on Friday, June 30th. Leerink Swann cut NxStage Medical from an “outperform” rating to a “market perform” rating and upped their price objective for the stock from $28.00 to $30.00 in a research report on Tuesday, August 22nd. Stephens cut NxStage Medical from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $33.00 to $30.00 in a research report on Wednesday, August 9th. Finally, William Blair cut NxStage Medical from an “outperform” rating to a “market perform” rating in a research report on Monday, August 7th. One analyst has rated the stock with a sell rating and nine have given a hold rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $30.25.

NxStage Medical, Inc. (NASDAQ NXTM) opened at 27.75 on Friday. The firm’s market capitalization is $1.83 billion. The stock’s 50 day moving average price is $27.80 and its 200 day moving average price is $25.85. NxStage Medical, Inc. has a 52-week low of $20.45 and a 52-week high of $30.80.

NxStage Medical (NASDAQ:NXTM) last issued its earnings results on Monday, August 7th. The medical device company reported ($0.03) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.03). The company had revenue of $92.20 million during the quarter, compared to the consensus estimate of $96.47 million. NxStage Medical had a negative return on equity of 2.43% and a negative net margin of 1.33%. The firm’s revenue for the quarter was up .0% compared to the same quarter last year. During the same period last year, the business posted ($0.03) EPS. On average, analysts predict that NxStage Medical, Inc. will post ($0.05) EPS for the current fiscal year.

NxStage Medical Company Profile

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Want to see what other hedge funds are holding NXTM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NxStage Medical, Inc. (NASDAQ:NXTM).

Institutional Ownership by Quarter for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.